Literature DB >> 25281924

MicroRNA-874 inhibits cell proliferation and induces apoptosis in human breast cancer by targeting CDK9.

Ling Wang1, Wen Gao2, Fan Hu1, Zhiyang Xu1, Fuqiang Wang3.   

Abstract

It has been demonstrated that miR-874 plays important roles in many types of cancers. Nevertheless, its biological function in breast cancer remains largely unknown. In this study, we found that the expression level of miR-874 is down-regulated in breast cancer in comparison with the adjacent normal tissues. The overexpression of miR-874 is able to inhibit cell proliferation and induce cell apoptosis and cell cycle arrest in MCF7 and MDA-MB-231 cells. Using a bioinformatics method, we further show that CDK9 is a direct target of miR-874 and that its protein level is negatively regulated by miR-874. Therefore, the data reported in this manuscript demonstrate that miR-874 is an important regulator in breast cancer and imply that the miR-874/CDK9 axis has potential as a therapeutic target for breast cancer.
Copyright © 2014. Published by Elsevier B.V.

Entities:  

Keywords:  Apoptosis; Breast cancer; CDK9; Cell cycle; Cell proliferation; miR-874

Mesh:

Substances:

Year:  2014        PMID: 25281924     DOI: 10.1016/j.febslet.2014.09.035

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  24 in total

1.  Cyclin-Dependent Kinase Inhibitors as Anticancer Therapeutics.

Authors:  Mary E Law; Patrick E Corsino; Satya Narayan; Brian K Law
Journal:  Mol Pharmacol       Date:  2015-05-27       Impact factor: 4.436

2.  miR-874-3p mitigates cisplatin resistance through modulating NF-κB/inhibitor of apoptosis protein signaling pathway in epithelial ovarian cancer cells.

Authors:  Ying Wang; Chenming Yan; Junxia Qi; Chunyan Liu; Juan Yu; Huabin Wang
Journal:  Mol Cell Biochem       Date:  2021-10-30       Impact factor: 3.396

3.  miR-874 suppresses the proliferation and metastasis of osteosarcoma by targeting E2F3.

Authors:  Dong Dong; Yubao Gong; Debao Zhang; Huricha Bao; Guishan Gu
Journal:  Tumour Biol       Date:  2015-12-02

4.  MicroRNA-874-mediated inhibition of the major G1/S phase cyclin, CCNE1, is lost in osteosarcomas.

Authors:  Tanushree Ghosh; Akhil Varshney; Praveen Kumar; Manpreet Kaur; Vipin Kumar; Ritu Shekhar; Raksha Devi; Priyanka Priyanka; Md Muntaz Khan; Sandeep Saxena
Journal:  J Biol Chem       Date:  2017-11-06       Impact factor: 5.157

5.  MiR-874 inhibits metastasis and epithelial-mesenchymal transition in hepatocellular carcinoma by targeting SOX12.

Authors:  Tao Jiang; Lian-Yue Guan; Yan-Shuo Ye; Hong-Yu Liu; Rui Li
Journal:  Am J Cancer Res       Date:  2017-06-01       Impact factor: 6.166

Review 6.  ApoptomiRs of Breast Cancer: Basics to Clinics.

Authors:  Shivani Sharma; Praveen K Patnaik; Stella Aronov; Ritu Kulshreshtha
Journal:  Front Genet       Date:  2016-09-29       Impact factor: 4.599

7.  Downregulation of miR-874-3p promotes chemotherapeutic resistance in colorectal cancer via inactivation of the Hippo signaling pathway.

Authors:  Kaiqian Que; Yuanhe Tong; Ganbo Que; Li Li; Hongcheng Lin; Shuai Huang; Ruoyu Wang; Langlang Tang
Journal:  Oncol Rep       Date:  2017-10-17       Impact factor: 3.906

8.  miR-206 inhibits the growth of hepatocellular carcinoma cells via targeting CDK9.

Authors:  Chi Pang; Gang Huang; Kaili Luo; Yuying Dong; Fengtian He; Guankui Du; Man Xiao; Wangwei Cai
Journal:  Cancer Med       Date:  2017-09-21       Impact factor: 4.452

9.  DNA methylation mediated silencing of microRNA-874 is a promising diagnosis and prognostic marker in breast cancer.

Authors:  Lei Zhang; Da-Li Yan; Fan Yang; Dan-Dan Wang; Xiu Chen; Jian-Zhong Wu; Jin-Hai Tang; Wen-Jie Xia
Journal:  Oncotarget       Date:  2017-07-11

10.  MicroRNA-874 Functions as a Tumor Suppressor by Targeting Cancer/Testis Antigen HCA587/MAGE-C2.

Authors:  Xiao Song; Wenjie Song; Ying Wang; Jingjing Wang; Yan Li; Xiaoping Qian; Xuewen Pang; Yu Zhang; Yanhui Yin
Journal:  J Cancer       Date:  2016-03-20       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.